Phase I Study to Evaluate Safety of Ruxolitinib in Combination with Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
This is a clinical trial to assess the safety of ruxolitinib and venetoclax administered in combination for the treatment of patients with relapse or refractory acute myeloid leukemia (AML).
relapsed/refractory acute myeloid leukemia
Patients with relapsed or refractory acute myeloid leukemia
18 - 100
Healthy Volunteers Needed
Duration of Participation
At least one month or a minimum of 12 months follow-up from the first dose of study drugs. If there is clinical benefit with treatment study drug will be provided. We will follow you for up to 5 years following your first dose of study drug.
Uma Borate, MD